Obesity Management Market to Grow at a CAGR of 4.9% through 2027

High costs involved in the research & development (R&D) of obesity drugs, coupled with limited financial support, are collectively a great challenge for adoption of obesity management solutions. Additionally, long gestation time needed for R&D activities, and the inclusion of clinical trials required to test these drugs hikes the expenditure significantly. Considering this scenario, manufacturers are being cautious while seeking better return on investments. In the long run, risks and limitations posed by the high development costs of obesity drugs are likely to impede the growth of the global obesity management market.

Future Market Insights’ latest publication estimates that the global market for obesity management will showcase an average growth during the forecast period, 2017-2027. In this period, the market is estimated to grow from US$ 641.6 Mn in 2016 to US$ 1,078.9 by 2027-end, representing a value CAGR of 4.9%. Between 2017 and 2027, the global obesity management market is poised to witness an incremental $ opportunity of over US$ 400 Mn.

In addition the high costs for developing obesity management drugs, the market is also expected to witness restraints from poor healthcare infrastructure in emerging markets. Stringent laws imposed upon drug manufacturers are also impacting the market’s growth. These laws are becoming more ambiguous, resulting into a slow-down in drug production. Moreover, studies revealing side effects of obesity management drugs are also causing major disturbance among regulatory bodies and manufacturers. GlaxoSmithKline plc., VIVUS, Inc., Novo Nordisk A/S, Arena Pharmaceuticals, Inc., F. Hoffmann La Roche Ltd., and Orexigen, Therapeutics, Inc. are companies profiled in the report as leading participants of global obesity management market.

A regional analysis of global obesity management market, compiled in the report, projects that North America’s share on global revenues will surpass 33% towards the end of 2027. North America is anticipated to emerge as the largest market for obesity management in the world. Western Europe will also be at the forefront, bringing in an estimated US$ 222 Mn in revenues by 2027-end. Across different regions in the world, a majority of obesity management drugs will be distributed through hospital pharmacies. With more than 50% share in global revenues, hospital pharmacies will remain the largest distribution channel for obesity management drugs throughout the forecast period.

In terms of surgery, the global demand for obesity management drugs is primarily concentrated towards treatments namely, gastric bypass surgery and gastric sleeve surgery. In addition to this, the report also projects that over one-third of global obesity management revenues will be accounted by global sales of liraglutide drugs. Demand for phentermine and topiramate drugs will also gain traction, registering revenue growth at 7% CAGR. Nonetheless, fastest revenue growth will be recorded by global sales of bupropion and naltrexone drugs, revenues from which will surpass US$ 100 Mn by end of 2027.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-587

Western Europe Medical Recruitment Market to Rise US$ 21.2 Bn by 2028

Over the last decade, healthcare and pharmaceutical industries have witnessed growth across various countries of Western Europe. Moreover, healthcare-related research projects in Western Europe would impact the growth of recruitment services across the region. The Western Europe medical recruitment market is estimated to be valued at US$ 21.22 Bn by the end of 2028, expanding at a moderate CAGR of 3.1% during the forecast period 2018-2028.

Increase in healthcare spending, prevalence of chronic diseases, and the growing population-employment ratio are some factors likely to propel the Western Europe medical recruitment market in the coming years. Germany is projected to exhibit relatively high growth over the forecast period. Increasing prevalence of heart-related diseases and presence of a large number of homecare centres are among major factors fuelling the growth of the medical recruitment market in Western Europe.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-we-3675 

Future Market Insights, in its report on the ‘Western Europe Medical Recruitment Market’ has analyzed and investigated various trends and developments shaping the market. The report also assays a holistic view of the current drivers, trends, and opportunities in the medical recruitment market. FMI has also presented an in-depth understanding of financials, key strategies, and developments of various medical recruitment agencies such as Medacs Healthcare, Euromotion Medical, CPL Healthcare, ProClinical Recruitment, TFS Healthcare, EGV Recruiting, and CCM Recruitment. The report also presents a list of recommendations to the stakeholders in the medical recruitment market.

Burgeoning Pharma Industry and Research Activities to Push for Increased Medical Recruitments

Flourishing medicine development coupled with enhanced production, exports and R&D expenditure is likely to play an important role in increasing the demand for medical recruitment services. Moreover, increase in the employment of new workforce in the region is also expected to drive the medical recruitment market in Western Europe. In the past few years, owing to technological advancements, companies and governments are conducting research on innovative technologies. These research activities require technicians, nurses, lab assistants, medical representatives, pharmacists, and physicians, which in turn, would drive the demand for medical recruitment services in Western Europe during the forecast period.

Key Trends Shaping the Future of the Western Europe Medical Recruitment Market Through 2028

• Since medical institutions churn out a large number of healthcare professionals, recruitment agencies and medical establishments are partnering with educational institutions to tap on potential job aspirants and candidates. The nursing/healthcare staff segment is projected to dominate the medical recruitment market with more than 29% value share. Paramedic staff segment would also witness steady growth in the coming years, owing to the increase in in healthcare organization and CROs.
• Recruiting companies are leveraging the giant networks of social media to enhance their recruiting, selection ability and staffing processes. Medical recruitment agencies are using LinkedIn recruiting solutions to explore potential healthcare candidates.
• With the emergence of new HR technologies like application tracking systems and recruitment marketing platforms, medical recruitment agencies are using Big Data and Analytics to find right candidates and improve cultural fit and retention.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-we-3675 

Channel and expansion strategies along with product innovation and partnerships with other healthcare recruitment agencies are among key strategies adopted by major players in this market to boost their sales.

Respiratory Devices Market to Attain a Value of US$ 34.17 Billion by 2027

The global respiratory devices market was valued at nearly US$ 13 billion in 2016. It is projected to grow at 9.2% CAGR during the period 2017-2027 to reach US$ 34.17 billion in revenues.

Demand for respiratory devices will continue to be driven by increasing ageing population and rising prevalence of COPD and obstructive sleep apnea. Increasing emphasis on healthcare spending in developing countries, especially in Asia Pacific and Latin America, will continue to positively influence the growth of the market.

Adoption of non-invasive techniques in pulse oximeters and advancement in full polysomnography testing are also favourably impacting the growth of the market.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-794 

Although Future Market Insights maintains a positive outlook on the global respiratory devices market, premium pricing, budgetary constraints, and increasing use of generic product types can impede the growth of the market.

The key trends expected to influence the global respiratory devices market in the foreseeable future are,

• Portable and wearable devices are steadily gaining popularity among patients owing to ease-of-use and flexibility in carrying the devices.
• Growing demand for stationary oxygen concentrator with pulse flow technology and rechargeable batteries.
• Increasing demand for respiratory devices in Asia Pacific on account of rising prevalence of chronic obstructive pulmonary diseases. Multinational companies are focusing on consolidating their position in developing countries to leverage upon the emerging opportunities.

Positive Airway Pressure Devices Account for the Highest Demand

According to Future Market Insights’ research, positive airway pressure devices currently account for the highest demand. This segment accounted for nearly 29% revenue share of the market in 2017; by 2027, this is projected to increase to 34.6%. In terms of revenues, positive airway pressure devices segment is projected to reach US$ 11.81 billion in revenues by 2027.

Other key product types by revenue are respiratory consumables (respiratory masks, nasal cannulas, tracheostomy tubes and oxygen tubes) and pulse oximeters.

Future Market Insights also offers market forecast and analysis on other key respiratory devices, including nebulisers, oxygen concentrators, polysomnography devices, mechanical ventilators, and spirometers.

Hospitals Largest End-users

By end-user, the key segments include hospitals, ambulatory surgical centres, clinics, and long-term care centres. Currently, hospitals account for the highest demand for respiratory devices, followed by ambulatory surgical centres and long-term care centres. Demand for respiratory devices from hospitals was worth US$ 5.18 billion in 2016; by 2027, this is projected to grow at 9.8% CAGR to reach US$ 14.36 billion.

U.S. Continues to Account for Significant Percentage of Global Sales

The U.S. remains the largest market for respiratory devices globally. On the back of strong sales in the U.S., the North America respiratory devices market accounted for over 40% revenue share of the market in 2016. Future Market Insights projects North America to remain the largest market for respiratory devices during the period 2017-2027.

Western Europe and APEJ are the other leading markets for respiratory devices. These two markets collectively accounted for a revenue share of over 35% in 2016.

Future Market Insights, in its report, has also profiled the respiratory devices market in Latin America, Eastern Europe, Japan, and MEA.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-794 

In its report, companies profiled by Future Market Insights are Massimo Corporation, Teleflex Incorporated, Fisher & Paykel Healthcare Limited, ResMed Inc, Hamilton Medical AG, Medtronic PLC, Koninklijke Philips N.V., Smiths Medical, General Electric Healthcare Limited, Drägerwerk AG & Co. and KGaA, Inogen Inc.

Intra-Abdominal Pressure Measurement Devices Market to Witness an Outstanding Growth During 2016 – 2026

According to Future Market Insights’ survey on physician practice pattern concerning intra-abdominal pressure measurement devices, 33.9% physicians admitted to never measuring bladder pressure in the ICU.

(All figures available in the report)

Rising prevalence of intra-abdominal hypertension (IAH), combined with development of DEHP-free products is fuelling demand for intra-abdominal pressure measurement devices. According to a new research by Future Market Insights, the global intra-abdominal pressure measurement devices market will grow at a CAGR of 16.5% to reach US$ 173.3 Mn by 2026.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2612 

The report predicts adoption of intra-abdominal hypertension (IAH) to witness steady adoption in developing countries. Currently, bulk of the demand for these devices is concentrated in America and Europe. Asia Pacific, Latin America, and GCC are among the regions where demand for intra-abdominal pressure measurement devices will grow steadily during the forecast period.

According to Future Market Insights, collaboration between intra-abdominal pressure measurement device manufacturers and catheters for measuring IAP in ICUs is growing. Further, owing to better sensitivity and accuracy of these devices, many physicians are preferring clinical examination of IAH over physical detection.

Use of intra-abdominal pressure measurement devices in abdominal procedures was estimated at 1,472,000 in 2016. Future Market Insights estimates it to reach 7,246,000 by 2026.

North America continued to be the leader in the number of abdominal pressure measurement procedures in 2016. Of the 1,472,000 procedures carried out in 2016, North America accounted for 647,000. It is pertinent to mention that Canada’s share of abdominal procedures was negligible, accounting for only 44,000 procedures in 2016. The U.S. continues to remain the country where a majority of abdominal pressure measurement procedures were conducted in 2016. Western Europe was the second highest region, with 275,000 procedures, whereas Asia Pacific excluding Japan (APEJ) was at third position.

By product type, Future Market Insights offers analysis and forecast on disposables and equipment. According to the study, disposables segment accounted for higher revenue share of the overall market in 2016. Future Market Insights estimates this trend to continue during the forecast period 2016-2026.

By application type, Future Market Insights has segmented the market into intra-compartment pressure and intra-abdominal hypertension. Demand for intra-abdominal pressure measurement devices was higher for intra-abdominal hypertension. This segment was valued at US$ 32.5 Mn in 2016.

By end-user, hospitals accounted for the highest demand for intra-abdominal pressure measurement devices in 2016. Trauma centres, clinics, and ambulatory surgical centres were the key application segments.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-2612 

Leading intra-abdominal pressure measurement device manufacturers include C. R. Bard, Inc., Stryker Corporation, Holtech Medical, ConvaTec Group PLC, and Biometrix Ltd. According to the report, C. R. Bard, Inc. accounted for nearly 30% revenue share of the global intra-abdominal pressure measurement devices market. Stryker Corporation and Holtech Medical were the other key players by market share.

Prefilled Formalin Vials Market Value Projected to Expand by 2028

The growth of the healthcare industry is expected to play a vital role in shaping the future prospects of the prefilled formalin vials market. Formalin is a derivative of formaldehyde, and prefilled formalin vials are used for tissue fixation. According to a latest research by Future Market Insights (FMI), the global prefilled formalin vials market is projected to account for over US$ 515.8 Mn, in terms of value, by 2028 end. The report on prefilled formalin vials market projects significant growth potential with average compound annual growth rate pegged at 4.1% through 2028.

Prefilled Formalin Vials Market: Overview

According to the new European rules and guidelines, it is essential to protect the environment and the health of the workers who work in an environment where they are directly exposed to aldehydes. Emission of formalin fumes in pathology labs can lead to serious health hazards. The discharge of these fumes can be avoided by using chemical hoods, particularly in operation theatres, where formalin is mostly used. The need to lower the level of formalin emission has surged the demand for prefilled formalin vials, and the growth of the prefilled formalin vials market. In the medical ambulatories including ambulatory surgical centers where small biopsies are performed, the challenges associated with formalin usage are dealt primarily by using prefilled formalin vials or tubes. Direct exposure to formalin increases the risk of developing cancer. Prefilled formalin vials limit the risk of direct exposure to formalin. This factor, in particular, is likely to play an instrumental role in driving the growth of the prefilled formalin vials market.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-7582

The prefilled formalin vials can be used for diversified applications in distinct end-use settings such as forensic labs, CROs, emergency medical services, diagnostic laboratories, and veterinary laboratories, among others. Formalin being a cost-effective method of histopathological diagnosis plays a vital role in the healthcare industry, as it cuts down the unnecessary costs associated with the procedural changes related with the usage of new alternative fixatives. In the European Union (EU) in 2017, 971,000 workers were estimated to be exposed to formaldehyde above the background level. Out of these, 175,380 were registered in Italy. Formaldehyde is commonly known to have acute toxicity, resulting in sensory irritation in the eyes and upper respiratory tract. The demand for formalin from veterinary clinics and forensic laboratories has remained stable, but is likely to decline in the near future. This is primarily to due to strict regulations regarding the usage of formalin across the globe.

Prefilled Formalin Vials Market: Segmental Analysis

Prefilled formalin vials are commercially available in different packaging forms in the global prefilled formalin vials market. Of these, 90 – 500 mL prefilled formalin vials are high in demand in the global prefilled formalin vials market, owing to the fact that there is no alternative fixative validated to be served as formalin replacement. Likewise, the 40 – 60 mL prefilled formalin vials segment is also projected to hold significant revenue share as their adoption is increasing in diagnostic and forensic laboratories. Diagnostic laboratories and CROs performing cancer research and diagnostics are the primary consumers of prefilled formalin vials. According to FMI, the contract research organizations segment accounted for over 28.8% revenue share in the global prefilled formalin vials market in 2017.

Formalin is a cost-effective method of histopathology diagnostic in the West and East Asia, owing to which the demand for prefilled formalin vials has increased in the region. Furthermore, the growing incidence of cancer in Asia Pacific due to changing lifestyle of people is likely to boost the growth of the prefilled formalin vials market in the region. Presence of large number of companies with sole focus on providing high-quality prefilled formalin vials and rising disposable income in Japan are factors expected to surge the demand for prefilled formalin vials in the country.

FMI has segmented the global prefilled formalin vials market based on product type and end users. In terms of revenue, the 90 – 500 mL product type segment in the prefilled formalin vials market is expected to hold significant share over the forecast period. In contrary, the <10 mL product type segment in the prefilled formalin vials market is expected to exhibit limited investment opportunities, in terms of revenue, through 2028.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-7582

Prefilled Formalin Vials Market: Key Players

The report tracks some of the key companies operating in the prefilled formalin vials market, such as Diapath S.p.A, Histo- Line Laboratories Srl, Cardinal Health, Inc., Leica Microsystems Sales GmbH (Leica Biosystems Nussloch GmbH), Genta Environmental Ltd., Carl Roth GmbH + Co. KG, Magnacol Ltd., Serosep Limited, Ultident Scientific and Solmedia Limited.

Photorejuvenation Equipment Market: Increased Demand for Minimally Invasive Aesthetic Correction Procedures Fuelling Adoption

Advancements in laser technologies over the years have contributed to various applications of cosmetic treatments, contributing to the growth of the global photorejuvenation equipment market. Rising technological advancements with an increasing number of skin problem are anticipated to increase the adoption of photorejuvenation equipment globally. According to the latest research by the company, the global photorejuvenation equipment market is anticipated to account for over US$ 3,100 Mn, in terms of value, by 2028 end. The report on photorejuvenation equipment is expected to show significant growth potential with an average Y-o-Y growth rate pegged at 6.3% through 2028.

Global Photorejuvenation Equipment Market: Overview & Analysis

Rising incidence of skin problems leads to scarring. Acne causes major physical changes which include permanent scarring. Furthermore, nearly 85% of people aged between 12 and 24 experience acne. The commonly used non-invasive treatment for acne scarring is laser resurfacing. The effectiveness of photorejuvenation equipment are widely accepted in dermatology for the treatment of a variety of cutaneous conditions. Thus, the rising prevalence of such skin problems is triggering the growth of the global photorejuvenation equipment market over the forecast period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-7559

Manufacturers are adopting strategic approaches in order to increase the product reach in the photorejuvenation equipment market. Increasing demand of photorejuvenation equipment for non-invasive photorejuvenation treatments, with frequent product approvals and advancements in photorejuvenation equipment technology, are further boosting the strategic activities like mergers and collaboration agreements among manufacturers and driving the photorejuvenation equipment market growth. Companies operating in the photorejuvenation equipment market are also continuously focusing on increasing the photorejuvenation equipment reach globally. As a result, they are adopting distribution agreements as an expansion strategy to gain maximum revenue share in the global photorejuvenation equipment market. Furthermore, advancements in laser technologies over the years have contributed to various applications of cosmetic treatments, contributing to the growth of the global photorejuvenation equipment market.

Increasing healthcare spending is an indicator of improvement in the healthcare setting as a whole. Increase in the budget of hospitals would indicate the use of better quality equipment's and thus drive the growth of the global photorejuvenation equipment market. According to the IMF, healthcare spending is expected to increase by over 6% yearly, based on the current GDP forecast.

However, high treatment cost and adverse side effects related to the photorejuvenation equipment may hamper the growth of the global photorejuvenation equipment market. Treatment with photorejuvenation equipment, including surgeries and non-invasive treatments, are associated with high costs making them inaccessible to people in the low middle-income groups. Also, non-invasive treatments with photorejuvenation equipment require a series of sessions to achieve the desired result, which results in a high overall cost of the treatment. Furthermore, the duration of treatment, number of sessions and the cost of treatment depend on the area being treated. These factors are directly responsible for dropping the growth of the global photorejuvenation equipment market.

According to the company, the laser equipment segment accounted for over 75% revenue share in the overall photorejuvenation equipment market in 2017. However, the growing popularity of LED and IPL might limit the segment’s growth in the near future. China photorejuvenation equipment market is expected to be the most lucrative market in the global photorejuvenation equipment market during the forecast period.

The company has segmented the global photorejuvenation equipment market into Intense Pulsed Light (IPL) Equipment, Laser Equipment, and LED Equipment. In terms of revenue, the laser equipment segment in photorejuvenation equipment will hold maximum revenue share over the forecast period.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-7559

The company’s report tracks some of the key companies operating in the photorejuvenation equipment market, such as Hologic Inc. (Cynosure, Inc.), Lumenis, Syneron Medical Ltd., Lynton Lasers Ltd, EL.EN. S.p.A. (Deka Mela S.r.l.), Fotona, Cutera, Inc., Lutronic Corporation, Beijing Nubway S & T Co., Ltd, and others.

Next Generation Optical Biometry Devices Market Poised to Reach US$ 450 Mn by 2028

Increasing incidence of eye diseases such as cataract and refractive errors coupled with rising number of eye care clinics and hospitals globally are factors increasing the adoption of next generation optical biometry devices. With the advancement in the technology, next generation optical biometry devices have been developed aiding measurement of eyes before cataract and refractive surgeries. Earlier measurement by ultrasound technique was gold standard. However, unlike next generation optical biometry devices, ultrasound devices require direct contact of the probe, which lead to many eye infections.

The next generation optical biometry devices are automated and measure many parameters such as the axial length, anterior chamber depth, thickness of the lens, retinal thickness, pupil size and many more. The next generation optical biometry devices are an accurate alternative for the precise measurements and provide efficient results. Also the next generation optical biometry devices avoid the operator variations measurements.  Research indicates next generation optical biometry devices market is anticipated to account for revenues over US$ 450 Mn, by 2028 end. The report on next generation optical biometry devices projects market revenues to expand at a CAGR of 5.1% through 2028.

According to Prevent Blindness organization, ~25 Mn Americans having cataract require medical care every year in the U.S., hence boosting demand for next generation optical biometry devices. Similar rising demand for next generation optical biometry devices is noted in UK with rising number of cataract surgeries. Increased demand for next generation optical biometry devices is noted in developing markets concurrent with access to eye care facilities. Next generation optical biometry devices are all-in one devices used for evaluation of lens and refraction, of retina.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-7556

Next Generation Optical Biometry Devices Market: Overview & Analysis

Rapid increase in number of probe infections due to usage of ultrasound devices, lead to post-operative errors fuelling demand for next generation optical biometry devices instead of ultrasound biometry devices. Manufacturers of next generation optical biometry devices are introducing automated devices which are more efficient in measuring segments of eyes. Players in next generation optical biometry devices market are working on strengthening the software, which could provide detailed information about eye segments. New next generation optical biometry devices introduced are taking into account irregularities and astigmatisms of the anterior and the posterior surfaces of the eye. The next generation optical biometry devices uses a partially coherent wave that has approximately 9x the resolution of a 10 MHz sound wave, for precise measurement of axial length.

Hospitals end users segment account for 41.8% revenue share in the global Next Generation Optical biometry Devices market. Medical services and vision benefits offered under Medicare includes cataract surgeries; which will increase the demand of next generation optical biometry devices.

Increasing geriatric population and rising income in Japan is expected to surge the demand for more advanced Next Generation Optical biometry Devices. Japan Next Generation Optical biometry Devices market is estimated to create absolute $ opportunity worth approximately US$ 1.21 Mn between 2017 and 2028.

The company has segmented the global Next Generation Optical Biometry Devices Market into product type and end users. In terms of revenue, the swept source segment in product type in next generation optical biometry devices market report will account for significant revenue share over the forecast period. In contrary, the Partial coherence interferometry (PCI) based next generation optical biometry devices segment in all the markets will exhibit limited investment opportunities through 2028 in next generation optical biometry devices market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-7556

Next Generation Optical Biometry Devices Market: Key Players

The next generation optical biometry devices market report tracks some of the key companies, such as Carl Zeiss AG, Nidek Co Ltd, Haag-Streit AG(Metall Zug AG), Ziemer Ophthalmic Systems, Optovue, Incorporated, Topcon Corporation, TOMEY GmbH,  Movu Inc. (unit of Santec Corporation) , Newway Technology and  OCULUS Optikgeräte GmbH. The largest player in the next generation optical biometry devices market is Carl Zeiss AG with its IOL masters and Haag-Streit AG’s Lenstar.

Extremity Tissue Expanders Market to Grow US$ 1,842.6 Mn by 2028

Increasing aging population and rise in plastic surgery are the major factor which is fueling the growth of extremity tissue expanders market over the forecast period. According to a latest research by company, the global extremity tissue expanders market is anticipated to account for US$ 1,842.6 Mn, in terms of value, by 2028 end. The report on extremity tissue expanders further projects significant growth potential with average year-on-year growth rate pegged at 6.3% over the period of 2018-2028.

Extremity Tissue Expanders Market: Overview & Analysis

It is observed that reconstructive procedures has undergone a tremendous shift from the conventional invasive procedures to minimally invasive surgeries. Advancements and development of long-lasting improved extremity tissue expanders are expected to be the key factors driving the growth of the industry. Presently, advancements in technology have led to the development of the extremity tissue expanders, with an expansion of potential shape types. There are several limitations of the traditional and conventional medical surgeries, such as long recovery time, more chances of infection, and highly expensive procedures. These limitations have resulted in shift to minimally invasive procedures. Extremity tissue expanders today have become extremely versatile in nature with patient’s like-mindedness in going forward with the procedure. This transformation has led to a positive impact on the global extremity tissue expanders market growth. The number of surgeries with extremity tissue expanders is expected to increase with other prevalent factors supporting the rise of the extremity tissue expanders market in terms of adoption. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-7553

The availability alternative treatment options for reconstructive surgeries, may hamper the growth of the global extremity tissue expanders market. In order to leverage the presence of a large patient pool, various medical device companies involved in the extremity tissue expanders  market and new entrants are developing treatment options that can improve the care for reconstructive procedures. Moreover, the European Medical Agency has very stringent regulatory approval standards due to which most of the products fail to reach the extremity tissue expanders market. Several extremity tissue expanders manufacturers are focusing on the development of new products. However, due to stringent regulations and lengthy approval process, most of the products do not reach the extremity tissue expanders market, which hampers the growth of extremity tissue expanders market to a certain extent, and hence alternative treatment options are getting adopted. Market is segregated into definite terms but the lack of procedure and products in developing countries effect the overall extremity tissue expanders market growth and rise in alternative support care.

Breast reconstruction segment by product type is expected to dominate the global extremity tissue expanders market. Breast reconstruction segment is expected gain the market value of US$ 943.4 Mn in global extremity tissue expanders market during 2017. This is due availability of favorable reimbursement scenarios for the treatment of breast cancer. Breast reconstruction segment is of extremity tissue expanders by product type is also expected to grow at faster rate and it is anticipated grow ta CAGR of 6.3% over the period of 2018-2028 owing to rise in number of breast reconstruction procedure throughout the globe. Scalp reconstruction and oral and maxillofacial reconstruction segment of extremity tissue expanders market by product type is expected to be the less lucrative in term of value.

By shape type, anatomical segment of extremity tissue expanders market is expected to gain maximum market share and estimated to reach the market value of US$ 682.9 Mn in 2028. This is due variety of products with anatomical shape are available in the extremity tissue expanders market. Among all end user, hospital segment is expected to be the most lucrative segment for extremity tissue expanders market though maximum number if breast reconstruction surgery performed in the hospitals.

North America is the expected to dominate the global extremity tissue expanders market in term of value by region. North America region for extremity tissue expanders is estimated to gain market value of US$ 233.7 Mn in 2018, though this North America hold the maximum number of key manufacturers for extremity tissue expanders. After North America, extremity tissue expanders market is then followed by Europe and APEJ. By region APEJ is anticipated to show faster growth than other region in global extremity tissue expanders market and APEJ region is projected to grow at CAGR of 7.7% over the forecast period.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-7553

Extremity Tissue Expanders Market: Companies

FMI’s report tracks some of the key companies operating in the extremity tissue expanders market, such as GC Aesthetics Plc., Koken Co. Ltd., Allergan Plc., Mentor Worldwide LLC, Laboratories Arion, Wright Medical Group N.V. Groupe Sebbin SAS, Sientra Inc., Guangzhou Wanhe Plastic Materials Co. Ltd., and Guangzhou Wanhe Plastic Materials Co., Ltd.

Preterm Birth Diagnostic Test Kits Market Projected to Reach US$ 200 Mn By 2028

A new study by the company titled 'Preterm Birth Diagnostic Test Kits Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018–2028', has listed out the key points being considered by preterm birth diagnostic test kits companies to emerge and stay sustainably profitable in the long run in the preterm birth diagnostic test kits market. The global preterm birth diagnostic test kits market is expected to expand at a CAGR of 7.4% over the forecast period to reach a value of over US$ 200 Mn by 2028, and the North America preterm birth diagnostic test kits market is expected to remain as a main sink market for revenues. Europe is expected to remain as the main source market for preterm birth diagnostic test kits, as most of the preterm birth diagnostic test kits facilities are located in this region. However, with the increasing demand and cost-effective diagnostic options in countries such as China and India, and various countries of Asia Pacific and Middle-East, is fueling the growth of preterm birth diagnostic test kits market.

Key Findings Presented in the Report on the Preterm Birth Diagnostic Test Kits Market

The report finds that approximately 115.4 million birthsoccurred in 2017, out of which 11.1% births were preterm, which is approximately 12.8 million births. As per WHO, preterm birth complications are the leading cause of deaths amongst children under the age of 5, directly responsible for approximately 1 million death in 2015. Out of these, 3/4th of these deaths can be prevented with cost-effective interventions. The adoption rates for preterm birth diagnostic tests kits ranged from 2% to 15% distributed over various geographies. Majority of the existent patient pool are unaware about the cost-saving benefits of preterm birth diagnostic test kits, thus, a major portion on the preterm birth test kits market has remained untapped which remains open for manufactures of preterm diagnostic test kits to exploit the preterm birth diagnostic test kits market over the forecast period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-7551

Analysis of the Preterm Birth Diagnostic Test Kits Market

For preterm birth diagnostic test kits, blood sample is the most common sample take for diagnosing preterm labor and premature rupture of membrane. Blood sample-based preterm birth diagnostic tests in preterm cases are the most common and widely accepted in the preterm birth diagnostic test kits end users. However, vaginal discharge sample type preterm birth diagnostic tests are gaining popularity for preterm birth diagnostic test kits.

Hospitals, outpatient clinics & diagnostic laboratories using preterm birth diagnostic tests are the primary point of contact for patients experiencing preterm birth symptoms. Hospitals are estimated to account for majority of the revenue share under the end users segment for preterm birth diagnostic test kits market in 2017, owing to being the primary healthcare facility for preterm cases. The prevalent cases of preterm birth, growing demand for cost-effective diagnostic options and preterm birth test kits, and success in clinical studies for developing a rapid preterm birth diagnostic test kits is expected to fuel the growth of the global preterm birth diagnostic test kits market over the forecast period.

Activities across the preterm birth diagnostic test kits manufacturers are restricted to efficiency and specificity testing. The top activity associated with preterm birth diagnostic test kits manufacturers is joint collaboration with various organizations in order to spread awareness, further development, and test the sensitivity, specificity and efficiency of preterm birth diagnostic test kits.

Factors Impacting Growth of the Preterm Birth Diagnostic Test Kits Market

Rising focus on cost-effective diagnosis using preterm birth diagnostic test kits is expected to boost the growth of the preterm birth diagnostic test kits market. Preterm birth diagnostic test kits manufacturing companies focusing on spreading awareness about preterm birth diagnostic test kits and marketing preterm birth diagnostic test kits through campaigns and joint research studies is expected fuel the growth of the preterm birth diagnostic test kits market during the forecast period. However, Preterm birth diagnostic kits experience stiff competition from alternative product lines. Trans-vaginal scans, advanced ultrasound are some of the examinations adopted by healthcare providers over preterm birth diagnostic kits and would pose challenges to the growth of the preterm birth diagnostic test kits market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-7551

Preterm Birth Diagnostic Test Kits Market: Companies

Some of the key preterm birth diagnostic test kits companies analyzed in this report titled Preterm birth diagnostic test kits market include Creative Diagnostics, Qiagen, Medixbiochemcia, Hologic Inc, Sera Prognostics, IQ Products, Biosynex, Nanjing Liming Biological Preparations Co Ltd, Clinical Innovations LLC, BIOSERV Diagnostics GmbH, Wuxi BioHermes Biomedical Technology Co. Ltd, and Anhui Deep Blue Medical Technology.

Actinic Keratosis Treatment Market to Reach US$ 8 Bn by 2028

Awareness programs by non-profit organization about the actinic keratosis treatment have increased the awareness level among the people about the actinic keratosis treatment in developed economies, which is consequently expected to increase the value of actinic keratosis treatment market. The company’s latest research on global actinic keratosis treatment market reflects the market to account for revenues over US$ 8 Bn, by 2028 end. The report on actinic keratosis treatment further projects significant growth potential with high single digit average year-on-year growth rate over the period of 2018-2028.

Overview of the Actinic Keratosis Treatment Market

In the U.S., actinic keratosis is estimated to affect 10% of females and 26.5% males, while the prevalence of actinic keratosis in the U.K. is 15% in males and 6% in females. Additionally, people with high fat diet also tend to be at high risk of actinic keratosis. Thus, increasing prevalence of actinic keratosis is a major factor expected to drive the growth of the actinic keratosis treatment market over the forecast period. The availability of large volume of clinical evidence data for the actinic keratosis treatment has increased awareness among patient base who want to participate effectively in their own treatment journey for faster relief. This has also helps physicians and prescribers to understand the success rate different options for the actinic keratosis treatment in isolation and also in combination which will upsurge the revenue growth of actinic keratosis treatment market. The flexibility to choose treatments, especially combination treatments for faster patient relief - due to availability of clinical evidence documentation are factors expected to propel treatment innovation and thus the revenue growth of the actinic keratosis treatment market over the forecast period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-3233

Combination of topical fluorouracil and cryotherapy is the most commonly prescribed actinic keratosis treatment. The combination therapy of fluorouracil and cryotherapy for actinic keratosis treatment has success rate of around 90% for widespread multiple actinic keratosis lesion. This combination for actinic keratosis treatment has high success rate due to convenient administration, lower potential for irritation and systemic absorption of fluorouracil cream. Use of the fluorouracil cream for one week when combined with cryotherapy for actinic keratosis treatment improved outcomes versus cryotherapy alone, hence it is mostly prescribed by the medical professionals for better outcome of actinic keratosis treatment.

There are various options available for actinic keratosis treatment but the topical treatment is prescribed by the physicians as a first line of treatment. Topical medication for actinic keratosis treatment has a success rate of 25–60% in isolation, whereas photodynamic therapy is more successful in combination with various topical applications. Cost of topical medication for actinic keratosis treatment is much less compared to other options for actinic keratosis treatment, owing to which it has greater among preferred by the patients. Topical medication for actinic keratosis treatment includes gels and creams that can be self-prescribed and can be easily applied to the affected area of the body, which is also one of the reasons for the high preference of topical treatment for actinic keratosis. Besides, most of the topical creams and gels used for the actinic keratosis treatment are easily available in retail pharmacies and drug stores. Hence, topical treatment segment by product type for global actinic keratosis treatment market is expected to gain maximum market share in tem of value.

Actinic keratosis is a chronic skin disease, which can further transform to skin cancer, hence Medicare and Medicaid are providing reimbursements for the actinic keratosis treatment. Besides, various private health insurance companies in U.S. also reimburse the cost for actinic keratosis treatment. Medicare provides different CPT codes for the actinic keratosis treatment by different methods such as photodynamic therapy and cryotherapy. Favorable reimbursements scenario by Medicare and Medicaid are factors expected to boost the demand cryotherapy and photodynamic therapy for actinic keratosis treatment and in U.S. Therefore, North America is assessed to be most lucrative region for actinic keratosis treatment market. North America actinic keratosis treatment market is estimated to gain 34.8% market value share and anticipated to reach the market value of US$ 2,636.0 Mn by 2028.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3233

Actinic Keratosis Treatment Market: Companies

The report tracks the key companies operating in the actinic keratosis treatment market, such as GlaxoSmithKline plc., Novartis AG, Nestle SA, Sun Pharmaceutical Ltd.,  Bausch Health Companies Inc., Almirall, LLC, LEO Pharma Inc., Pierre Fabre Pharmaceuticals, Inc., Biofrontera , Cipher Pharmaceuticals Inc.

Vision Care Market to Surpass US$ 127,730 Mn, in terms of value by 2028

The increasing usage of electronic devices, changing lifestyle and hygiene have led to vision-related problems worldwide. The number of patients with vision-related problems have increased and so is the need for vision care products and services. According to the latest report published by the company, the global vision care market size is projected to account for over US$ 127,730 Mn, in terms of value, by 2028 end. The report further projects significant growth with an average CAGR of 7.1% through 2028.

Vision Care Market: Dynamics

According to the World Health Organization (WHO), approximately 285 million people are visually impaired worldwide. Out of these, 39 million people are blind and 246 million people have low vision. Most of the disorders & conditions causing visual impairment & blindness are preventable or readily treatable with known & cost-effective interventions, and normal vision can be restored with the help of eyeglasses, contact lenses or refractive surgery. Ageing is one of the prime factors responsible for vision-related problems. Population aged 65+ years is growing day by day and with it the demand for eye care-related products and solutions is also increasing. This increasing ageing population and the growing demand for vision care products are factors expected to create growth opportunities for the manufacturers globally. Healthcare initiatives by the Federal health care programs have increased the number of population opting for vision care benefits. Besides, the out-of-pocket costs have reduced due to insurance coverage. Likewise, in the U.S., “The Patient Protection and Affordable Care Act” has defined eye care for pediatric as an essential benefit. This factor, in particular, is likely to play an instrumental role in driving the growth of the vision care market.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-822

With a rapid increase in the internet usage, technological changes and number of research-based industries, the usage of laptops, mobiles, PCs and others electronic devices has increased in the day-to-day life, which is the major factor responsible for eye-related problems. To overcome this alarming situation, "VISION 2020 - The Right to Sight” a global action program is conducted by NGOs and private organizations in collaboration with the WHO to prevent avoidable blindness. Also, “VISION 2020” has initiated global campaigns to raise awareness among governments about the societal effects of blindness and to gather a strong, long-term political & professional commitment to reduce avoidable blindness. “VISION 2020” has taken initiatives to develop & strengthen the primary health/eye care methodology to prevent the avoidable blindness.

The growth of the vision care market is driven by the increase in lens prescriptions and eye care professionals such as optometrists and ophthalmologists. Most of the ageing consumers (65+) have low awareness regarding eye health. Product development, particularly for the ageing population, is a major challenge as ageing consumers tend to suffer from dry eyes due to which fitting of contact lens becomes difficult. Therefore, the products for ageing consumers need more attention. Elderly population prefers spectacles over contact lens due to low awareness regarding their benefits. According to the company, the spectacle lenses segment accounted over 40% revenue share in the global vision care market in 2017. However, the growing popularity of contact lens might limit the segment’s growth in the near future. Contact lenses offer vision correction for the entire field of the eye including peripheral vision. Soft contact lenses are safe for daily use and for sports as well. They do not fog and can be discarded if damaged. Besides, they are economic compared to prescribed glasses.

Vision Care Market: Regional Insights

In Europe and Northern America, more than 1 person in 5 was aged 60 or above in 2017. According to a survey by the WHO, 90% of the visually impaired population is in low- & middle-income countries. A significant share of this population is unaware regarding the preventive care for vision loss, available curative services and quality rehabilitation. Further, the growing number of ageing population with vision disorders in Asia Pacific is likely to boost the growth of the vision care market in Asia Pacific. Increasing geriatric population and rising disposable income in North America is expected to surge the demand for advanced vision care products and solutions. The North America vision care market is estimated to create an absolute $ opportunity worth US$ 21,735 Mn between 2018 and 2028.

Vision Care Market: Segmental Analysis

The company has segmented the global vision care market into spectacle lenses, contact lenses and cleaning & disinfecting solutions. In terms of revenue, the spectacle lenses and contact lenses segments are expected to hold significant shares over the forecast period. In contrary, the cleaning & disinfecting solutions segment in the vision care market is expected to exhibit limited investment opportunities, in terms of revenue, through 2028.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-822 

Vision Care Market: Companies

The report tracks some of the key companies operating in the vision care market, such as Bausch and Lomb (Acq. by Valeant Pharmaceuticals), Alcon (sub. Novartis AG), CooperVision and Johnson & Johnson, LUXOTTICA GROUP, Essilor, ZEISS International, Safilo Group and Rodenstock.

Global Cardiac Biomarker Diagnostic Test Kits Market to Reach US$ 2,540.8 Mn by 2028

According to the latest market report published by the company titled ‘Global Cardiac Biomarker Diagnostic Test Kits: Global Industry Analysis 2013–2017 and Opportunity Assessment, 2018–2028’, the global cardiac biomarker diagnostic test kits market is projected to expand at a CAGR of 5.1% during the forecast period 2018–2028 and reach US$ 2,540.8 Mn by the end of 2028.

Global Cardiac Biomarker Diagnostic Test Kits Market: Dynamics

Chest pain is a common emergency department (ED) presentation accounting for 8–10 million visits per year in the U.S. The increasing number of patient visits in the emergency department is expected to create growth opportunities for the cardiac biomarker diagnostic test kits market. Obesity has become a global health challenge in the past few decades, with every sixth person being obese. According to the WHO, the number of obese population around the globe has doubled in the last two decades. The growing obese population, which is at a high risk of developing cardiovascular diseases, is expected to consequently increase the demand for cardiac biomarker diagnostic test kits. Moreover, the leading manufacturers of cardiac biomarker diagnostic test kits are focusing on collaborating with universities and associations to develop and expand their product portfolio. On the other hand, less availability of novel cardiac biomarker diagnostic test kits due to tedious approval procedures is expected to hamper the growth of the cardiac biomarker diagnostic test kits market over the next decade.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-452

Global Cardiac Biomarker Diagnostic Test Kits Market: Forecast

The global cardiac biomarker diagnostic test kits market is segmented on the basis of product type, indication, end users and regions. On the basis of product type, the cardiac biomarker diagnostic test kits market has been segmented into Brain Natriuretic Peptide (BNPs) Test Kits, Creatine Kinase MB (CK-MB) Test Kits, Troponin (I&T) Tests Kits, Myoglobin Test Kits and other test kits. By product type, the BNP test kits segment dominated the global cardiac biomarker diagnostic test kits market with market value of US$ 682.9 Mn in 2017, and is expected to be the most lucrative segment throughout the forecast period. The BNP test kits segment in the global cardiac biomarker diagnostic test kits market is also projected to be the fast-growing segment, and to grow at CAGR of 6.8% over 2018–2028.

On the basis of indication, the cardiac biomarker diagnostic test kits market is segmented into Angina Pectoris, Acute Myocardial Infarction, Congestive Heart Failure, and others. By indication, the Angina Pectoris is expected to be the most lucrative segment in the cardiac biomarker diagnostic test kits market, and is estimated to account 45.2% value share in 2018 and to account for 41.4% value share by 2028 end, growing at a CAGR of 3.6%. The congestive heart failure segment by indication is expected to be the fast-growing segment in the cardiac biomarker diagnostic test kits market. The congestive heart failure segment is projected to grow at a CAGR of 6.7% over the forecast period to reach a market value of US$ 357.8 Mn by 2028.

On the basis of end users, the cardiac biomarker diagnostic test kits market has been segmented into hospitals, diagnostic laboratories, outpatient clinics, academic and research institutes. The diagnostic laboratories segment is expected to dominate the global cardiac biomarker diagnostic test kits market in 2018 as a large number of patients visit diagnostic laboratories for the diagnosis of cardiovascular disease. Revenue from the diagnostic laboratories segment is expected to increase at a CAGR of 5.9% over 2018–2028, to reach US$ 997.4 Mn by 2028.

On the basis of region, the cardiac biomarker diagnostic test kits market has been segmented into North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, China, Japan and Middle East & Africa. North America dominated the global cardiac biomarker diagnostic test kits market with maximum value share in 2017. Chest pain is a common emergency department (ED) presentation in the region accounting for 8–10 million visits per year in the U.S., among which 20% of patients are diagnosed with the help of cardiac biomarker diagnostic test kits for cardiovascular diseases. One-third share of the cardiac biomarker diagnostic test kits market by value is accounted by the U.S. due to increasing prevalence of cardiovascular diseases and rising adoption of cardiac biomarker diagnostic test kits. APECJ is expected to be the fast-growing regional markets for cardiac biomarker diagnostic test kits due to increasing number of obese population and expansion strategies followed by the key manufacturers in the region. Latin America and MEA are expected to witness sluggish growth in the global cardiac biomarker diagnostic test kits market due to low awareness regarding the benefits of cardiac biomarker diagnostic test kits for the diagnosis of cardiovascular diseases.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-452

Global Cardiac Biomarker Diagnostic Test Kits Market: Competitive Landscape

Examples of some of the key players operating in the global cardiac biomarker diagnostic test kits market are Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Siemens AG, bioMérieux SA, Randox Laboratories Ltd. The global cardiac biomarker diagnostic test kits market is highly fragmented, with top six players, estimated to account for approximately 75% market share. Abbott Laboratories accounted maximum share of the global cardiac biomarker diagnostic test kits market in 2017, due to the acquisition of Alere Inc., which has helped the company to expand its product portfolio. Acquisition is the key strategy followed by all the leading manufacturers of cardiac biomarker diagnostic test kits market to expand their business. The companies of cardiac biomarker diagnostic test kits market are focusing on acquiring local manufacturers to expand their product portfolio and also to increase their market share.